NantCell
Culver City
California
United States
12 articles about NantCell
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
NantCell Announces New Celgene Investment
1/5/2019
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th
-
Billionaire biotech entrepreneur Patrick Soon-Shiong has his eyes set on taking his newly formed oncology-focused Nant public this year.
-
CytRx Highlights Second NantCell Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients With Advanced Squamous Cell Carcinoma
2/6/2018
The first trial in pancreatic cancer patients commenced in January 2018.
-
CytRx Highlights Inclusion Of Aldoxorubicin In Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell
10/12/2017
-
CytRx Forges $356 Million Cancer Deal With Patrick Soon-Shiong's NantCell
7/28/2017
-
Despite 'Lowball' Offer, NantCell's Soon-Shiong Snags Altor BioScience In $290 Million Deal
6/27/2017
-
NantKwest And NantCell Announce FDA Authorization For The NANT Cancer Vaccine Clinical Trials, The First Novel Combination Of Innate And Adaptive Immunotherapy In Patients With Pancreatic Cancer
5/9/2017
-
NantCell Announces FDA Grant Of Orphan Drug Designation For The Company’s Ganitumab Monoclonal Antibody Therapy In Ewing Sarcoma
4/10/2017
-
World's Richest Doctor's Startup NantCell Rakes in Another $57 Million
1/26/2016
-
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
-
What You Need to Know About NantCell
12/2/2015